Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Effect of Spontaneous Breathing in APRV Mode on Respiratory Physiology of ARDS Patients (SBA-APRV)

torstai 27. elokuuta 2026 päivittänyt: XiaoJing Zou,MD, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

A Randomized Controlled Trial Of The Effect Of Spontaneous Breathing In APRV Mode On Respiratory Physiology In Patients With Acute Respiratory Distress Syndrome

This is a single-center, prospective, randomized, three-period crossover physiological study in adult patients with moderate-to-severe acute respiratory distress syndrome (ARDS, PaO₂/FiO₂ ≤150 mmHg). Each enrolled subject will receive all three APRV ventilation conditions in random sequence: low-level spontaneous breathing (spontaneous minute-ventilation proportion 10%-30%), high-level spontaneous breathing (31%-50%), and fully suppressed spontaneous breathing as control. A 30-minute wash-out period is set between each condition to restore unified physiological baseline. Primary outcome is ventilation-perfusion mismatch percentage (mismatch%) measured by Electrical Impedance Tomography (EIT). Secondary outcomes include EIT-derived pulmonary parameters, respiratory mechanics, hemodynamics, diaphragmatic function and safety profiles. Only short-term, reversible ventilator and sedation adjustments will be performed; routine clinical management remains unchanged throughout the trial.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

Acute respiratory distress syndrome (ARDS) is a life-threatening critical respiratory illness characterized by heterogeneous pulmonary injury and severe ventilation-perfusion mismatch. Airway Pressure Release Ventilation (APRV) permits spontaneous breathing throughout the whole respiratory cycle, which may improve regional ventilation-perfusion matching and hemodynamic status. Nevertheless, excessive spontaneous breathing effort may trigger pendelluft phenomenon, augment regional lung strain and precipitate patient-self-inflicted lung injury (P-SILI). To date, the safe intensity range of spontaneous breathing during APRV for moderate-to-severe ARDS patients has not been well defined.

This single-center, randomized 3-period crossover self-controlled physiological trial enrolls ICU adult patients aged 18-80 years, diagnosed with moderate-to-severe ARDS (PaO₂/FiO₂ ≤ 150 mmHg) within 48-hours of invasive mechanical ventilation. After written informed consent obtained from legal surrogates, subjects will first receive a 60-minute baseline ventilation period following ARDSnet low-tidal-volume pressure-control ventilation strategy under deep sedation without spontaneous breathing. Subsequently, every participant will undergo three APRV intervention states in computer-generated random order: Condition A: APRV with low-intensity spontaneous breathing (spontaneous-contributed minute ventilation 10%-30%); Condition B: APRV with high-intensity spontaneous breathing (31%-50%); Condition C: APRV with fully suppressed spontaneous breathing via deep sedation (RASS -4 to -5). Each intervention maintains target spontaneous-breathing intensity for 30-minute stabilization before data collection. A mandatory 30-minute wash-out phase will be implemented between successive interventions to revert subjects back to baseline pressure-control ventilation and sedation status.

Primary endpoint is the comparison of ventilation-perfusion mismatch percentage (mismatch%, calculated as sum of dead-space fraction and shunt fraction) among three states measured by bedside EIT. Secondary endpoints contain multiple EIT quantitative indices, respiratory mechanics parameters (including esophageal-pressure-derived transpulmonary pressure), hemodynamic and right-ventricular function, diaphragmatic ultrasound indices, arterial blood gas variables. Adverse events related to respiratory, circulatory and operational procedures are closely monitored as safety outcomes.

Planned sample size is 14-16 enrolled participants to achieve 12 evaluable subjects completing all three intervention sequences considering dropout rate. All ventilator and sedation modifications are short-term and reversible; standard clinical therapeutic regimens will not be altered except for study-related procedures. After finishing all three intervention periods, ventilator and sedation settings will be returned to clinical team's discretion. Linear mixed-effect models will be applied for statistical analysis of crossover-design data.

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

15

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

  • Nimi: Xiaojing Zou
  • Puhelinnumero: +86-27-85351606
  • Sähköposti: 249126734@qq.com

Opiskelupaikat

    • Hubei
      • Wuhan, Hubei, Kiina, 430022
        • Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
        • Ottaa yhteyttä:

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

  • Aikuinen
  • Vanhempi Aikuinen

Hyväksyy terveitä vapaaehtoisia

Ei

Kuvaus

Inclusion Criteria:

  • 1. Age ≥18 and ≤80 years old. 2. Diagnosed with moderate-to-severe ARDS according to the 2023 global ARDS definition.

    3. Within 48 hours of invasive mechanical ventilation. After 1-hour low-tidal-volume pressure-controlled ventilation following ARDSnet strategy, arterial blood gas shows PaO₂/FiO₂ ≤ 150 mmHg.

    4. Written informed consent is obtained from the patient or their legal surrogate decision-maker after full explanation of the study by the principal investigator or authorized study physician.

Exclusion Criteria:

  • 1. Refractory shock defined as persistent hyperlactatemia and/or prolonged capillary refill time, fluid-resistant, requiring norepinephrine ≥ 0.5 μg/kg/min.

    2. Severe chronic medical conditions severely affecting cardiopulmonary function: severe chronic obstructive pulmonary disease, interstitial lung disease, pulmonary embolism, right-heart failure, pulmonary hypertension, or severe arrhythmia.

    3. Radiologically confirmed bronchopleural fistula, status post lobectomy, or other major thoracic surgery.

    4. Contraindications to electrical impedance tomography (EIT): extensive chest skin injury or infection, implanted cardiac pacemaker or defibrillator, etc.

    5. Contraindications for esophageal manometry placement: esophageal obstruction, perforation, severe esophageal varices, etc.

    6. Diaphragmatic hernia, severe chest wall deformity, or significant pulmonary bullae.

    7. Significant coagulation abnormalities (PT or APTT prolonged ≥2 times upper limit of normal, or INR>2.0) with active bleeding risk.

    8. Severe intracranial hypertension (>20 mmHg), severe traumatic brain injury (GCS ≤8), or neuromuscular disorders.

    9. Pregnant or breastfeeding women. 10. Patients already receiving ECMO therapy. 11. Expected survival time <24 hours judged by attending physician. 12. Body mass index (BMI) >35 kg/m². 13. Previously enrolled in this study or participating in other interventional clinical trials.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Crossover-tehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Low-level spontaneous breathing under APRV
APRV ventilation with spontaneous-contributed minute-ventilation proportion maintained at 10%-30%. A stabilization period of 30 minutes is performed before data collection
APRV ventilation mode, spontaneous-contributed minute-ventilation proportion maintained at 10%-30%. 30-minute stabilization before outcome measurement.
Kokeellinen: High-level spontaneous breathing under APRV
APRV ventilation with spontaneous-contributed minute-ventilation proportion maintained at 31%-50%. A stabilization period of 30 minutes is performed before data collection.
APRV ventilation mode, spontaneous-contributed minute-ventilation proportion maintained at 31%-50%. 30-minute stabilization before outcome measurement.
Kokeellinen: Fully suppressed spontaneous breathing under APRV
APRV ventilation with spontaneous breathing completely suppressed by deep sedation (RASS-4 to -5). A stabilization period of 30 minutes is performed before data collection.
APRV ventilation mode, spontaneous breathing fully suppressed by deep sedation (RASS-4 to -5). 30-minute stabilization before outcome measurement.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Ventilation-perfusion mismatch percentage (Mismatch%)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Ventilation-perfusion mismatch percentage (Mismatch%), calculated as the sum of dead-space percentage and shunt percentage measured by electrical impedance tomography (EIT). A composite index reflecting overall ventilation-perfusion mismatch, assessed at baseline and under three APRV experimental conditions. Unit: %
Baseline and at the end of each 30-minute experimental condition during the study intervention period.

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Match percentage(match%)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Match percentage derived from electrical impedance tomography (EIT). Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Pendelluft amplitude
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Pendelluft amplitude derived from electrical impedance tomography (EIT). Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Dead-space percentage
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Dead-space percentage derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions. Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Shunt percentage
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Intrapulmonary shunt percentage derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions. Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Global inhomogeneity index (GI)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period
Global inhomogeneity index (GI) derived from electrical impedance tomography (EIT). Unit: unitless.
Baseline and at the end of each 30-minute experimental condition during the study intervention period
Center of ventilation (CoV)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Center of ventilation (CoV) derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions. Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Tidal recruitment-derecruitment
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Tidal recruitment-derecruitment (Tidal R/D) derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions. Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Ventilation distribution
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Regional ventilation distribution derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions. Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Perfusion distribution
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Regional pulmonary perfusion distribution derived from electrical impedance tomography (EIT), assessed at baseline and under three APRV experimental conditions. Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Peak airway pressure (Ppeak)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Airway peak pressure (Ppeak) measured by mechanical ventilator, assessed at baseline and under three APRV experimental conditions. Unit: cmH₂O
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Plateau pressure (Pplat)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Airway plateau pressure (Pplat) obtained from end-inspiratory hold maneuver, assessed at baseline and under three APRV experimental conditions. Unit: cmH₂O.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Driving pressure (ΔP)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Driving pressure (ΔP) derived from mechanical ventilator measurements. Unit: cmH₂O.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Static respiratory system compliance (Cstat)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Static respiratory system compliance (Cstat), assessed at baseline and under three APRV experimental conditions. Unit: mL/cmH₂O.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
End-inspiratory esophageal pressure (PesI)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
End-inspiratory esophageal pressure (PesI) measured by esophageal manometry, assessed at baseline and under three APRV experimental conditions. Unit: cmH₂O.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
End-expiratory esophageal pressure (PesE)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
End-expiratory esophageal pressure (PesE) measured by esophageal manometry, assessed at baseline and under three APRV experimental conditions. Unit: cmH₂O
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Esophageal pressure swing (ΔPes)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Esophageal pressure swing (ΔPes) measured by esophageal manometry, assessed at baseline and under three APRV experimental conditions. Unit: cmH₂O.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
End-inspiratory transpulmonary pressure (PtpI)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
End-inspiratory transpulmonary pressure (PtpI) derived from airway and esophageal pressure measurements. Unit: cmH₂O.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Transpulmonary driving pressure (ΔPtp)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Transpulmonary driving pressure (ΔPtp) derived from airway and esophageal pressure measurements. Unit: cmH₂O.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
End-expiratory transpulmonary pressure (PtpE)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
End-expiratory transpulmonary pressure (PtpE) derived from airway and esophageal pressure, assessed at baseline and under three APRV experimental conditions. Unit: cmH₂O.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Esophageal pressure-time product per minute (PTPes/min)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Esophageal pressure-time product per minute (PTPes/min) read directly from the ventilator interface. Unit: cmH₂O·s/min.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Dynamic transpulmonary driving pressure (ΔPL,dyn)
Aikaikkuna: At the end of each 30-minute APRV experimental condition (after stabilization)
Dynamic transpulmonary driving pressure (ΔPL,dyn) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort. Unit: cmH₂O.
At the end of each 30-minute APRV experimental condition (after stabilization)
Inspiratory muscle pressure (Pmus)
Aikaikkuna: At the end of each 30-minute APRV experimental condition (after stabilization)
Inspiratory muscle pressure (Pmus) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort. Unit: cmH₂O
At the end of each 30-minute APRV experimental condition (after stabilization)
End-expiratory occlusion pressure (ΔPocc)
Aikaikkuna: At the end of each 30-minute APRV experimental condition (after stabilization)
End-expiratory occlusion pressure (ΔPocc) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort. Unit: cmH₂O
At the end of each 30-minute APRV experimental condition (after stabilization)
Airway occlusion pressure (P0.1)
Aikaikkuna: At the end of each 30-minute APRV experimental condition (after stabilization)
Airway occlusion pressure (P0.1) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort. Unit: cmH₂O
At the end of each 30-minute APRV experimental condition (after stabilization)
Muscular pressure index (PMI)
Aikaikkuna: At the end of each 30-minute APRV experimental condition (after stabilization)
Muscular pressure index (PMI) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort. Unit: cmH₂O
At the end of each 30-minute APRV experimental condition (after stabilization)
Negative inspiratory force (NIF)
Aikaikkuna: At the end of each 30-minute APRV experimental condition (after stabilization)
Negative inspiratory force (NIF) obtained from ventilator measurements; only measured in the presence of spontaneous breathing effort. Unit: cmH₂O
At the end of each 30-minute APRV experimental condition (after stabilization)
Heart rate
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Heart rate from continuous bedside monitoring, assessed at baseline and under three APRV experimental conditions. Unit: beats per minute.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Mean arterial pressure (MAP)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Mean arterial pressure (MAP) measured via invasive arterial catheter, assessed at baseline and under three APRV experimental conditions. Unit: mmHg.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Vasopressor dosage (μg/kg/min)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Dosage of vasoactive medications, assessed at baseline and under three APRV experimental conditions. Unit: μg/kg/min
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Central venous pressure (CVP)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Central venous pressure (CVP), assessed at baseline and under three APRV experimental conditions. Unit: mmHg.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Right-ventricular fractional area change
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Right-ventricular fractional area change measured by transthoracic echocardiography, assessed at baseline and under three APRV experimental conditions. Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Velocity-time-integral (VTI)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Velocity-time-integral (VTI) measured by transthoracic echocardiography, assessed at baseline and under three APRV experimental conditions. Unit: cm.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Tricuspid annular plane systolic excursion (TAPSE)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Tricuspid annular plane systolic excursion (TAPSE) measured by transthoracic echocardiography, assessed at baseline and under three APRV experimental conditions. Unit: mm.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Cardiac output (CO)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Cardiac output (CO) calculated from velocity-time integral (VTI) measured by transthoracic echocardiography, assessed at baseline and under three APRV experimental conditions. Unit: L/min.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Stroke volume (SV)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Stroke volume (SV) calculated from velocity-time-integral (VTI) measured by transthoracic echocardiography, assessed at baseline and under three APRV experimental conditions. Unit: mL.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Diaphragm displacement
Aikaikkuna: At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
Diaphragm displacement measured by bedside diaphragm ultrasound, assessed in two out of the three APRV experimental conditions only when spontaneous breathing was present. Unit: mm.
At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
Diaphragm thickening fraction
Aikaikkuna: At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
Diaphragm thickening fraction measured by bedside diaphragm ultrasound, assessed in two out of the three APRV experimental conditions only when spontaneous breathing was present. Unit: %.
At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
Lung 12-zone ultrasound score
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Lung ultrasound score based on 12-zone lung ultrasound assessment, assessed at baseline and under three APRV experimental conditions. Unit: unitless.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Overdistension (OD) pixel count
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Pixel count of lung overdistension (OD), exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: pixels.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Overdistension (OD) proportion
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Proportion of lung overdistension (OD) relative to total lung-region pixels, exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Recruitment (CR) pixel count
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Pixel count of lung recruitment (CR), exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: pixels.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Recruitment (CR) proportion
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Proportion of lung recruitment (CR) relative to total lung-region pixels, exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Atelectasis (AT) pixel count
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Pixel count of lung atelectasis (AT), exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: pixels.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Atelectasis (AT) proportion
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Proportion of lung atelectasis (AT) relative to total lung-region pixels, exported directly from electrical impedance tomography (EIT) software basic module, averaged over complete respiratory cycles within selected time interval, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.

Muut tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Incidence and severity of adverse events
Aikaikkuna: During each APRV experimental intervention period
Incidence and severity of adverse events during study interventions, focusing on respiratory events, circulatory events and procedure-related adverse events. Unit: unitless.
During each APRV experimental intervention period
Rate of premature intervention discontinuation for safety concerns
Aikaikkuna: During each APRV experimental intervention period
Rate of premature discontinuation of study interventions due to safety-related reasons. Unit: %.
During each APRV experimental intervention period
Inspired oxygen fraction (FiO₂)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Set inspired oxygen fraction, obtained directly from ventilator readings, recorded at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Arterial pH
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Arterial blood pH measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: unitless.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Arterial partial pressure of oxygen (PaO₂)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Arterial partial pressure of oxygen measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: mmHg.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Arterial partial pressure of carbon dioxide (PaCO₂)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Arterial partial pressure of carbon dioxide measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: mmHg.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Arterial oxygen saturation (SaO₂)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Arterial oxygen saturation measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: %.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Bicarbonate (HCO₃-)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Serum bicarbonate (HCO₃-) measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: mmol/L.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Base excess (BE)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Base excess (BE) measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: mmol/L.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Arterial lactate (Lac)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Arterial lactate (Lac) measured from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: mmol/L.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
PaO₂/FiO₂ ratio
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
PaO₂/FiO₂ ratio calculated from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: unitless.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Alveolar-arterial oxygen difference (A-aDO₂)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Alveolar-arterial oxygen difference calculated from arterial blood gas analysis, measured at baseline (prior to intervention, after stabilization) and at the end of each 30-minute APRV experimental condition (after stabilization). Unit: mmHg.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Correlation analysis among multiple respiratory-hemodynamic-diaphragm parameters
Aikaikkuna: Corresponding study time points
Explore the correlations among EIT parameters, respiratory mechanics, blood gas analysis, hemodynamics and diaphragm function across three study conditions.
Corresponding study time points
Ventilatory ratio (VR)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Ventilatory ratio (VR), a calculated index reflecting pulmonary dead-space and lung injury severity, is computed from minute ventilation and arterial CO₂ values assessed at baseline and under three APRV experimental conditions. Unit: unitless.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Expired tidal volume (VTe)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Expired tidal volume assessed at baseline and under three APRV experimental conditions. Unit: mL.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Total respiratory rate
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Total respiratory rate assessed at baseline and under three APRV experimental conditions. Unit: breaths/min.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Total minute ventilation
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Total minute ventilation assessed at baseline and under three APRV experimental conditions. Unit: L/min.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Spontaneous minute ventilation
Aikaikkuna: At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
Spontaneous component of minute ventilation assessed under two APRV experimental conditions only when spontaneous breathing was present, derived directly from ventilator readings. Unit: L/min.
At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
Proportion of spontaneous minute ventilation
Aikaikkuna: At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
Proportion of spontaneous minute ventilation relative to total minute ventilation, calculated under two APRV experimental conditions only when spontaneous breathing was present. Unit: %.
At the end of 30-minute APRV experimental conditions with spontaneous breathing effort (after stabilization)
Mechanical power (MP)
Aikaikkuna: Baseline and at the end of each 30-minute experimental condition during the study intervention period.
Mechanical power of ventilation as an indicator of ventilator-induced lung injury (VILI) risk, obtained directly from ventilator readings at baseline and under three APRV experimental conditions. Unit: J/min.
Baseline and at the end of each 30-minute experimental condition during the study intervention period.

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Tutkijat

  • Päätutkija: xiaojing zou, MD, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Torstai 1. lokakuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Sunnuntai 1. marraskuuta 2026

Opintojen valmistuminen (Arvioitu)

Tiistai 1. joulukuuta 2026

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Torstai 20. elokuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Torstai 27. elokuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Tiistai 1. syyskuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Tiistai 1. syyskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Torstai 27. elokuuta 2026

Viimeksi vahvistettu

Lauantai 1. elokuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • PROTO-APRV-2026-01
  • MR-42-26-065895 (Muu tunniste: National Medical Research Registration and Filing Information System of China)

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

EI

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa